ONC212 Trademark

Trademark Overview

On Friday, September 8, 2023, a trademark application was filed for ONC212 with the United States Patent and Trademark Office. The USPTO has given the ONC212 trademark a serial number of 98171918. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Monday, March 31, 2025. This trademark is owned by Chimerix, Inc.. The ONC212 trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals and pharmaceutical preparations for use in the treatment of oncological and neurological diseases and disorders
onc212

General Information

Serial Number98171918
Word MarkONC212
Filing DateFriday, September 8, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateMonday, March 31, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 13, 2024

Trademark Statements

Goods and ServicesPharmaceuticals and pharmaceutical preparations for use in the treatment of oncological and neurological diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, October 1, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameChimerix, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDurham, NC 27713
Party NameChimerix, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDurham, NC 27713

Trademark Events

Event DateEvent Description
Saturday, January 6, 2024ASSIGNED TO EXAMINER
Tuesday, September 12, 2023NEW APPLICATION ENTERED
Sunday, October 1, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 20, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, June 20, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, June 20, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, January 6, 2024NON-FINAL ACTION WRITTEN
Saturday, January 6, 2024NON-FINAL ACTION E-MAILED
Saturday, January 6, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 19, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, March 19, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, June 20, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, July 1, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 1, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 1, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 2, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 13, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 8, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 13, 2024PUBLISHED FOR OPPOSITION
Monday, March 31, 2025SOU TEAS EXTENSION RECEIVED
Monday, March 31, 2025SOU EXTENSION 1 FILED
Monday, March 31, 2025SOU EXTENSION 1 GRANTED
Tuesday, April 1, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

neurological diseases disorders oncological treatment pharmaceutical preparations pharmaceuticals